The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
STRIDE
2 other identifiers
observational
350
0 countries
N/A
Brief Summary
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2026
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 19, 2026
CompletedFirst Posted
Study publicly available on registry
May 29, 2026
CompletedStudy Start
First participant enrolled
July 31, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2029
Study Completion
Last participant's last visit for all outcomes
November 30, 2029
May 29, 2026
May 1, 2026
2.9 years
May 19, 2026
May 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (16)
Participant Characteristics
Age
End of study (24 months after the last participant is enrolled)
Participant Characteristics
Sex
End of study (24 months after the last participant is enrolled)
Patient Characteristics
Height in meters
End of study (24 months after the last participant is enrolled)
Participant Characteristics
Weight in kilograms
End of study (24 months after the last participant is enrolled)
Patients Characteristics
BMI in kg/m\^2
End of study (24 months after the last participant is enrolled)
Patients Characteristics
Smoking and cannabis status/type/history
End of study (24 months after the last participant is enrolled)
Patient Characteristics
Medical History
End of study (24 months after the last participant is enrolled)
Patient Characteristics
Baseline disease characteristics
End of study (24 months after the last participant is enrolled)
Patient Characteristics
Emphysema status
End of study (24 months after the last participant is enrolled)
Patient Characteristics
Disease severity
End of study (24 months after the last participant is enrolled)
Patient Characteristics
Eosinophil value
End of study (24 months after the last participant is enrolled)
Patient Characteristics
COPD-relevant vaccination status
End of study (24 months after the last participant is enrolled)
Patient Characteristics
Prior and current medications
End of study (24 months after the last participant is enrolled)
Patient Characteristics
Previous and current comorbidities
End of study (24 months after the last participant is enrolled)
Patient Characteristics
Reason(s) for initiation of dupilumab treatment
End of study (24 months after the last participant is enrolled)
Patient Characteristics
Insurance Provider
End of study (24 months after the last participant is enrolled)
Secondary Outcomes (9)
COPD Exacerbations
End of Study (24 months after the last participant is enrolled)
FEV changes
End of study (2 years after the last participant is enrolled)
Changes in Quality of Life
End of study (2 years after the last participant is enrolled)
Events
End of study (2 years after the last participant is enrolled)
COPD Exacerbations
End of study (24 months after the last participant is enrolled)
- +4 more secondary outcomes
Study Arms (2)
Cohort 1: COPD participants prescribed dupilumab
350 COPD consented participants prescribed dupilumab with prospective data collection
Cohort 2: Control COPD participants not prescribed dupilumab
750 COPD control participants from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. These participants will not be consented with retrospective data collection.
Interventions
medicine already approved by the FDA
Usual care that patients receive
Eligibility Criteria
COPD patients who are newly referred to start dupilumab treatment
You may qualify if:
- COPD patients who are newly referred to start dupilumab treatment
- Age ≥ 40 years
- Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit
You may not qualify if:
- Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI)
- Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments
- Patients currently participating in any interventional clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sanofilead
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 24 Months
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 19, 2026
First Posted
May 29, 2026
Study Start (Estimated)
July 31, 2026
Primary Completion (Estimated)
June 30, 2029
Study Completion (Estimated)
November 30, 2029
Last Updated
May 29, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- Study Duration
- Access Criteria
- Qualified researchers
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org